Opko Offers Glimpse at Oligo Medicines Efforts | GenomeWeb

Opko Health last month provided an update on its oligonucleotide medicines efforts, stating that it has programs in orphan neurologic and genetic disorders.

In early 2011, Opko acquired Curna, an early-stage developer of non-coding RNA-based drugs (GSN 2/3/2011). Since that time, however, the company has been quiet on the progress of Curna's programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.